These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17997200)

  • 1. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.
    Campbell GR; Senkaali D; Watkins J; Esquieu D; Opi S; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2007 Dec; 25(50):8441-7. PubMed ID: 17997200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 infected patients have antibodies recognizing folded Tat.
    Mediouni S; Baillat G; Darque A; Ravaux I; Loret E
    Infect Disord Drug Targets; 2011 Feb; 11(1):57-63. PubMed ID: 21303342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.
    Nicoli F; Chachage M; Clowes P; Bauer A; Kowour D; Ensoli B; Cafaro A; Maboko L; Hoelscher M; Gavioli R; Saathoff E; Geldmacher C
    BMC Infect Dis; 2016 Jul; 16():344. PubMed ID: 27450538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients.
    Re MC; Vignoli M; Furlini G; Gibellini D; Colangeli V; Vitone F; La Placa M
    J Clin Virol; 2001 Apr; 21(1):81-9. PubMed ID: 11255101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.
    Mediouni S; Watkins JD; Pierres M; Bole A; Loret EP; Baillat G
    J Biol Chem; 2012 Apr; 287(15):11942-50. PubMed ID: 22362765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Goldstein G; Chicca JJ
    Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
    Gupta S; Mitra D
    Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans.
    Senkaali D; Kebba A; Shafer LA; Campbell GR; Loret EP; Van Der Paal L; Grosskurth H; Yirrell D; Kaleebu P
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):587-94. PubMed ID: 18366309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications.
    Ronsard L; Lata S; Singh J; Ramachandran VG; Das S; Banerjea AC
    PLoS One; 2014; 9(1):e85452. PubMed ID: 24465566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications.
    Teto G; Fonsah JY; Tagny CT; Mbanya D; Nchindap E; Kenmogne L; Fokam J; Njamnshi DM; Kouanfack C; Njamnshi AK; Kanmogne GD
    Viruses; 2016 Jul; 8(7):. PubMed ID: 27438849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.
    Kashi VP; Jacob RA; Shamanna RA; Menon M; Balasiddaiah A; Varghese RK; Bachu M; Ranga U
    PLoS One; 2014; 9(12):e114155. PubMed ID: 25531437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma.
    Demirhan I; Chandra A; Hasselmayer O; Biberfeld P; Chandra P
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):364-8. PubMed ID: 10634198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers.
    Noonan DM; Gringeri A; Meazza R; Rosso O; Mazza S; Muça-Perja M; Le Buanec H; Accolla RS; Albini A; Ferrini S
    J Acquir Immune Defic Syndr; 2003 May; 33(1):47-55. PubMed ID: 12792355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
    Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
    New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.